Hacker News
- FDA Approves Lilly's Zepbound (Tirzepatide) for Chronic Weight Management https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-zepboundtm-tirzepatide-chronic-weight 94 comments
- New drug Donanemab Significantly Slowed Decline of Early Alzheimer's Disease https://investor.lilly.com/news-releases/news-release-details/lillys-donanemab-significantly-slowed-cognitive-and-functional 2 comments
- Tirzepatide delivered up to 22.5% weight loss in obese or overweight adults https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-delivered-225-weight-loss-adults-obesity-or 21 comments
- Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks https://investor.lilly.com/news-releases/news-release-details/treatment-tirzepatide-adults-pre-diabetes-and-obesity-or 18 comments science
- If Eli Lilly acquired RIGL, how would this impact RIGL's stock price? https://investor.lilly.com/news-releases/news-release-details/lilly-and-rigel-enter-strategic-collaboration-develop-ripk1 6 comments stocks
- Eli Lilly reports successful Phase 3 study for weight loss drug, with 63% of participants losing at least 20% of body weight on highest dose. https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-delivered-225-weight-loss-adults-obesity-or 158 comments science